ADMINISTRATION OF ROSIGLITAZONE IN PATIENTS WITH SLEEP APNEA

睡眠呼吸暂停患者服用罗格列酮

• 批准号: 7625761
• 负责人: ALEXANDROS N VGONTZAS
• 金额: $ 5.74万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625761
• 关键词: Central obesity; Clinical; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Insulin Resistance; Obstructive Sleep Apnea; Patients; Research; Research Personnel; Resources; Severities; Sleep Apnea Syndromes; Source; United States National Institutes of Health; rosiglitazone

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary hypothesis of this study is that insulin resistance/visceral obesity is a pathogenetic factor in obstructive sleep apnea and is a primary determinant of its clinical severity.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的主要假设是胰岛素抵抗/内脏肥胖是阻塞性睡眠呼吸暂停的发病因素，也是其临床严重程度的主要决定因素。